GMDA - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Gamida Cell Conference Call for the Second Quarter 2020 Results. My name is Baxter, and I will your operator for today. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. advised request. call be at being Please Cell’s Gamida Instructions] that is today’s recorded [Operator

would to Investor I Jaren Communications. Now, like go Madden, conference, for Please Vice Ms. today’s President ma'am. of ahead, Relations Corporate introduce and your host

Jaren Madden

good update the release Earlier across Thank an the to which today’s will the morning, second results where this for financial Company today's and a results on quarter we website everyone. call you, is morning, Welcome call. XXXX. which during press Baxter, we our financial our progress issued of and available summarizing you on release provide and can related review Company, at www.gamida-cell.com find press our to

Officer; Financial Chief Lankry, Ronit and Shai Here and Scientific Officer, Officer; Simantov, is me with our Executive call Medical Chief on Lodie, today Officer. our Tracey Chief Chief Julian Adams,

open prepared remarks, we our Following the will Q&A. call for up

forward and therapeutic development about we strategies During statements our expenses looking and call, our projected of potential commercial expectations future operational and runway. candidates, operating product may plans this cash our and clinical including objectives, make and plans, the

that we the future Julian now result update And our only a time-to-time. risk Our in over events, to including and in differ actual what important not views caution as from project may the These due that represent Gamida Form like filings results other turn otherwise. statements the you to section of from in number today considerations with materially today I'd described or forward-looking of factors SEC the a and information, Adams. whether risk to the we of them our may factors, XXF makes Cell new of as call future, we

Julian Adams

with for you, cell patients to Thank Cell, provide And cancers are hematologic diseases. with we thanks At and committed Gamida cures serious therapies the developing for everyone blood to rare joining us potential morning. to this Jaren.

through the challenges continued of COVID-XX. to We navigate have

top-line our across FDA III our of business, health randomized year, from data the and marrow approved progress made have positive first while bone Omidubicel, safety be source the for graft of Phase this global the Earlier reported employees. important We transplant. could protecting which study we

making killer candidate or our cell NK therapy are cell cell second also malignancies has tumors. natural in the both a therapy, GDA-XXX, with progress which We and solid hematologic potential

Omidubicel; we into the III half anticipated of completed programs highly with provides our new runway we And from in we'll to clinical significant of the our a highlight hemologic our Additionally, positive XXXX. malignancies transplant. of Today, patients we've follow-on Omidubicel data with offering first Starting May, in a months. high-risk executive reported our need and cash that talent few team. added review over marrow top-line Phase next clinical milestones bone study second in

the from data generate report year. to to continuing study, are endpoints We and in quarter this secondary the fourth expect this of

track the a on initiate are basis XXXX. of on launch which BLA the potential submission rolling in second to us for fourth half We the quarter, positions a in

FDA potential with making Omidubicel following services patient programs. good comprehensive and other progress assistance to key required to including approval, We bring are activities patients developing also hospital

readiness, own we our manufacturing facility. of manufacturer Regarding build the Lonza, our out transfer and have tech contract finished completed the to

to cell cell be finished potential validation therapies GDA-XXX. end year. expansion now the for expect our tremendous are We of which entering care phase, hematologic offered malignancy. we Omidubicel which NK this generation platform the the to validated of transforming by led of the also

of and in cartese the our cell early results therapy allogeneic of to striking advanced harnesses multiple cells. I of safety the our to We offering novel homing demonstrated more a potential patients profile. GDA-XXX, have off-the-shelf Data approach lymphoma. the responses with ADCC to of a of is develop address with expansion potential are dependent Phase our potentially antibody goal study from which response similar viva ongoing NK known power lymphoma, With uniquely cell technology, as the efficacy an while with pioneering to favorable killing pleased limitations complete rates improves in that cytotoxicity be GDA-XXX in cytotoxic

We are planning lymphoma cryopreserved to I with in using in study initiate patients multicentered a a Phase formulation XXXX. to

waves by Our for as an through The in and second XXXX. half COVID-XX implementing hope is result this for first our our compelling, including been of that Covid if work serve labs a IND pathway. basis safety registration is could submission we the in IND expect to of emerged. the shift approval timeline trial submit data This additional study are of accelerated the as has shift measures the a impacted

has for both Celgene brings including As Officer. companies Ms served leadership over Korfin a prepare expanded several on novel where of worked XX She years role Operating operations regarded Michele of launch oncology experience clinical potential and Korfin as our Chief appointed of our highly to Commercial and therapies. in advance business we've and year, of In most she the recently and team. was programs at commercialization Access. Chief of President July, next focused Market we Kite

and of to additional capabilities brings teams. more and I'll years Simantov, to Metivier, Ronit Both Officer Human next start XX Resources. of experience and Ronit? talent further look look Chief our bring Matthew attract appointed resources into to commercial the the Omidubicel GDA-XXX. we of new particular have role we Vice update over Michele their than Matt turn in and now building week, to a provide we Gamida Matt As Medical Cell, to officially human forward call on President our contributions. also out

Ronit Simantov

and good our Julian, with our highlight morning milestones I'll beginning Omidubicel. program This review everyone. Thank upcoming and morning, you,

our XXX hematologic Phase noted we positive data study Omidubicel global reported high-risk in May, Julian top-line from As with in malignancies. III of patients

hospitals. The this signifying to collaborators median working days the forward. received the in primary the healthy the patient field time time quickly well-executed In XX appreciate compared community and days the and The our marrow is help in trial, of is rigorous, because also previously for is fewer make engraftment to patients engraftment seen modalities, to is in to XX neutrophil the to cells neutrophil blood move meaningful days. was patients other difference We key stem the for These neutrophil X.XXX. from with endpoint are favorably than transplant. time randomized established p-value with for and other analysis transplant how a recovery in proud hospitalizations, to was This randomized transplant significant began comparative group we who patients, and treat XX engraftment a with and XX transplant milestone became we've very Phase the to the of faster Omidubicel support study ranging to in truly which to X/X from cord are studies associated new infections data has shorter compared been us standard data where were consistent cells. reported less physicians engraftment, a our clinically bone intent to that to

Additionally, comparator patients Omidubicel achieved patients successful who transplanted XX% well the generally XX% were compared patients of protocol per who in neutrophil to of group. among tolerated; was engraftment received Omidubicel

continuing continue patient the is work we clinical in fashion. sites as Our blinded follow-up a with team study closely to

least all at include patients. will months post-transplantation six readout data next of Our follow-up for

patients be as of the will of compared comparator as out patients group. the alive in evaluating days for infections, to well the and incidence Specifically, Omidubicel we hospital

is achieve evaluate neutrophil longer will we endpoint, platelet engraftment. than engraftment secondary which to takes Another

expect press peer-review details top will We for but of a release preserve presentation line a to the by make announcement end via in the year. forum the

also By accessible as a XX% of eligible a spend to providing reduce could available patients serve for on data, bone time are a for but confident we we our graft to donor a a primary make more endpoint potentially transplant patient matched Omidubicel who the any are that based marrow Importantly, marrow of graft, the patients waiting transplant, unable in can transplant. Omidubicel match. transplant donor. need find currently bone for readily can today

in criteria. is coming of open study This meet we As transplant people our in open-label US to at who for arm currently bone to open to three need provide and sites marrow we recently risk Phase in hematologic work access sites to an the a protocol Omidubicel high are study the with III expected additional single initiated have study, are months. complete and malignancies,

observational collecting for with study International Center with how treatment into the patients includes CIBMTR year, to transplant The fits contemporaneous outcomes collect Omidubicel bone Marrow Last various receive and marrow We analyze with the marrow and agreement real hematologic to from are paradigm. malignancies, transplant data Research of world the III data allogeneic sources. donor research Blood further bone or study. Phase our an health understanding in who we also Transplant established a

in our underscores at We presentation be Next commitment in continuing hematologic Cord for initial anemia, Omidubicel malignancies, Blood evaluate with an outcomes Connect sponsored from to Omidubicel X/X life study are has improving in potential poster study and month This the severe believe will investigator a meeting. patients research reported data disorder. rare threatening the blood beyond virtual to aplastic patients. we this and Phase a

from quarter. study fourth in report this We to additional the data expect

In GDA-XXX, our cells addition to promise Omidubicel, natural that innate cells immune killer cancer. program tremendous have advancing we're treating NK for or held

expand functionality. several face development ability the including field preserving the NK in However, culture to challenges to their while cells

and GDA-XXX designed to data patients safety ongoing this our to lymphoma in and I dose. with addresses in and The challenge non-Hodgkin's technology determine the proof-of-concept. with the is recommended monoclonal X study myeloma combination Phase Our of antibodies initial provide multiple Phase assess

have reported partial response patient with We that achieved lymphoma, previously achieved the X complete and response. XX patients X among non-Hodgkin a the

those large responses B-cell activity of early data While observed this from small the single studies a is pretreated CAR-T favorably diffuse including a lymphoma with site, heavily observed in in compares patients therapy. set with

dose to no there continued importantly limiting no and GDA-XXX. observed. safety with also were no of In neurotoxicity XX be We profile patients, and toxicities the GvHD impressed

the ask questions the response are evaluate study of development we and the duration to primary inform future to objectives the to With of opportunity plans. taking complete, additional

GDA-XXX patients re-treated successfully we example, without lymphodepletion. with For

to advancing data the in programs and you expect our with clinical few look I forward Shai data over study and this in With fourth a review that, report team I financial to their to sharing COVID Shai? call will updated pandemic, just to to studies our turn commitment months. I results. both of of am during the our from We year. quarter proud this very from the

Shai Lankry

second quarter results the XXXX. will Thank you, Today, of our and Ronit, morning, financial good I everyone. for summarize

$X million activities. expenses net XXXX. same of by cash grants General for sale readiness December finance million of As The cash offering of the XX, same $XX we decreasing to primarily for $XX.X to $X.X aggregate XXXX, compared XXXX were to was Israel the expenses for last to for million year. second the warrants to the same XX, which in mainly million The GDA-XXX increase same resulting million by on XXXX. owned in for offset the total quarter compared the to our and million a received period compared non-cash of for loss have last security and equivalents expenses the due $X.X of $X.X due of proceeds from Authority. the Administrative compensation income The the was public million Research the the expenses year. $X.X compared and revaluation Development June quarter period XXXX. Net same commercial million XXXX activities million in to million the million. from net both quarter from cash includes non-cash of and follow was advancement The period in increase were to Commercial mainly in income approximately $X.X XX, recent $XX.X were quarter of position quarter were period the and Finance was net for Omidubicel $XX.X and income for June as related decrease attributed $XX.X expenses was clinical million, for shareholders. compared available net XXXX. $X to Innovation period

operational current that activities activities will We funding use and may turn million. expect our activities be total This of business to operating cash development this excludes the back second year that call for million that, I any will cash ongoing from our additional Julian. cash undertaken. continue received We for next plans, the With guidance year. into is ongoing to runway based support to be over on may $XX position $XX half anticipated range operating current to our

Julian Adams

Shai. Thanks, Shai. Thanks,

we and positive the about from are pandemic our conclude to to our have opportunities endpoints global very and during secondary With with new compelling and resilience I'd initiating we and study, filing. working our have registrational the consistent are we company Cell months away lymphoma in Phase strong like a work a BLA the in if are X and to advance GDA-XXX, who tremendous reporting With a study. thanking all Omidubicel, therapies this which ahead. data hard initiate could to to employees bring by We’re trial transition Gamida excited own patients. ongoing as the shown cell commitment the dataset

will open call we Operator? Now, the for questions.

Operator

from And comes Instructions] Piper Jaffray. from your question the line Ted first [Operator of Tenthoff

Your line is open.

TedTenthoff

Congrats and the regulatory to KOL III level the -- progress. run for been community? a the A you've so mean by I much. you company. clearly these but How would I question impressive digested on to it's and and commercial you've the Thanks not hires. by new win leaders breaking a really started congrats pretty time out prep the feedback all has say datasets as opinion say you high agree just filings just for you being launch. a know patients. on guys difficult of kind ultimately would Phase you data What do as are started as as

JulianAdams

Ronit, Ted thanks your that question. take would you for and

RonitSimantov

Thank incredibly the the such for endpoint execution are meaningful has the which a and Thanks. as of and significant response you, from for first high study, clinical Ted standpoint primary been quality second a very and positive results, well. KOL

response enthusiasm with interactions BLA approval. there's large we've the going to US the and So bring this we and and the had community is forward transplant in a in potential to general submission of number of globally, lot so positive; ultimately as overwhelmingly KOLs both

JulianAdams

FDA have also very with received We've agency And the from the as also data may shared add well. positive feedback to and if that. I

TedTenthoff

Okay. That’s great.

data more the to forward back Looking in half.

Operator

next of from the line from our And Evercore. comes question Jonathan Mueller

line Your is open.

JonathanMueller

ones. taking much Thanks so for the I quick question. two guess

characteristics much active in driver looks differences least this the guess indication NK at myeloma, efficacy, question these is in my NHL I versus the program First, initial more towards and you've capacity in forward manufacturing beyond much is, in of combo you the data available manufacturing be with or out. -- how about to do NHL's much which demand you indication of there next expect look expect it that to building able the ask then capacity starting I and you infrastructure also with for commercial the MAB most that meet we the been indication if goes secondly, other question to as building internal of that is out be the you’d and antibody and that trials successful year? How wanted whichever programs along Omidubicel? think the a or is And answer the the be to the do that is

JulianAdams

Tracey So cover your part GDA-XXX, let the me answer first question invite of on the manufacturing, to question. second and I’ll

Tracey Lodie

non-Hodgkin's see your going. high that more Ronit the then about it lymphoma. comments and the afterwards in Thank response seeing the to Sure. And rate on really over overall we’re for in has first to we're patients, that you, we Jonathan where we're turn I’ll if Obviously, she remission complete and indication question. the excited rate

a you believe is cell we we’re those we’ve receiving to NK difference with that the which that is seen is an and to distinct humanized recall really SLAMFX all And pointed elotuzumab, antibody as antibody you are on also As that combination present monoclonal do out antigen multiple there GDA-XXX. including anti myeloma, which patients due seeing. is

cells cells these that or laboratory antibody obviously and data auto suggesting combination to the suicide. these have in of causing -- themselves is we with this So fratricide causing this killing is animal the recognize actually NK

it’s itself is myeloma that cells modifying being and our brand program would multi as and So rate clinical IND this in known where not antibody. as not and are even moment single future order approved we not not agent, as of as in non-Hodgkin future. think research to that NK focusing is multiple using have single and a the combination a rituximab such different it's different effective. with think And efficient as In that we're of just a given working successful we're a not our for even MMR as and and effective see a as actually as elotuzumab remission a But target with it’s that in address we we ADCC with trial. we addition, multiple in high effective that it’s agent, single And for as in just we to agent. as in just antibodies complete for lymphoma

next think I hoping So to comment year. and to those I'll turn Ronit it our in over patients IND we're on see to what

RonitSimantov

of decision we've we Yes. study include benefit those make patients in lymphoma, we to We’ve that to I separately. the initiate cohorts. seen obviously seen in for both lymphoma enough plans there Phase of differently patient to analyzed results and believe because those types in a our to and multi-center indolent be expect with global and both of But and will aggressive patients each study

JulianAdams

manufacturing; on this with morphed Lonza all relationship agreement. say first, a had our the commercial to has continues, I'd been supply so question like manufacturing a and into that and that And of that we've relationship agreement, studies, clinical supplied longstanding commercial contract

built we've have for so we addition, of manufacturing. facility own In sites will business and out redundancy two our

community are years. out launch both continuously and in capacity to intending to market forecast, We at build that to treat the the our to be able subsequent serve and to doing research we project us enable are manufacturing

JonathanMueller

to that is guys prepared you solid didn't to start program. in your might see Okay. I you for direction? that first XXX remarks thing now that a then we plans you the mentioned follow guess tumor Thank about when hear Can much. talk I very that question. one motion talk up you in just about One

JulianAdams

Tracey, lab about want talk to you early do results? our

Tracey Lodie

talk can that. I Sure. about

we program antibodies. different ability right said to combine unique now. Obviously, have research because active with a an We have GDA-XXX we as

other a Herceptin very in setting activity good and research seen have with antibodies. We

to preclinical tumors. now editing, target us actually that be combination our gene as into guide are that performing activities ongoing studies NK actually the make right well we're the amenable studies, tumor we around actually antibody cells GDA-XXX which solid other best we have solid as disclosing which research will will not now to which for So

that an solid definitely which work GDA-XXX. we that it's us will preclinical on, be area beneficial that So of could we're most think when this for focusing will area with allow into guide and tumors more the have we

Operator

the question next Breidenbach comes from Your of from line Mark Oppenheimer.

open. line is Your

MarkBreidenbach

questions. us in I for GDA-XXX patients at remind little could ASH of the that good for presumably my of us you of that’s into numbers terms in main the morning taking between guidance to you'll be you if the your and and expect could of Hey, and was wondering just bit year? maybe a about thanks advancing update give version own study next the version differences clinic GDA-XXX now the

RonitSimantov

that talk it Tracey turn over for then about over I'll I'll and hand version. -- to the

Sound good?

JulianAdams

That Yes. sounds perfect.

RonitSimantov

thanks Mark. So,

we've continue you to European Bone decided despite hold but later a again with remember even to efficacy of In throughout the update as pleased have until to Transplant an X of larger terms in development an Marrow months COVID; study Phase outcome, product and that have at patients University this off been able we from by enroll to update at was Minnesota, plans lymphoma. patients. our and entire we're and since move be meeting, the of seen for this incremental the the There number time expect canceled what was meeting seen in side of for in already a ultimately study order last supposed update human number we enough increase year give in safety was we The to patients -- last on the we've study that forward the been of first the really shown. was an they've over to postponed where the

JulianAdams

suffice responses the to data that to in first and we've look it continue seen encouraging the patients. But say the consistent with XX

MarkBreidenbach

differences that between Okay. of GDA-XXX [Multiple terms Speakers] And of in -- version your

JulianAdams

Shai, cover Yes, you could that?

ShaiLankry

you. Yes. Thank can. I

from you is you're patient after in that of the Minnesota tech version Gamida the Cell. GDA-XXX manufactured aware and I'll under remind the right transfer at that’s and as used being direction So, now

now at this to product it's and product and fresh product, has last is given a haplo back patients. manufacturing of tremendously day half is quarters our a team the through XX which the of The So with hard first fresh to come timeline cryopreserved this two year year the formulation. up that’s still worked

our shelf the formulation goal GDA-XXX. is completely So of we're to really excited allogeneic a off have now cryopreserved that

formulation we even have this working. So that cryo pandemic shift through completed in

the get and We cell manufacturing have we're scale able -- the maintained of facility. post up a the in now That working op. then clinical maintained been has that activity to validation for to complete of implementing formulation said, process being the GMP that

and this So be the cryopreserved. completely and main will off-the-shelf differences are that

MarkBreidenbach

the be Okay. data That’s TR are observational from necessary with follow-up, is CIB or initial or are the process? Omidubicel to a respect completely helpful. included from this these And going with separate data that study, BLA and to

RonitSimantov

dataset So exploring we're a with paradigm. modalities is broader of variety this one in world understand what Omidubicel of the that role of to the the real order transplant is paradigm better sort treatment in and transplant understand transplant to graft

And so these studies to aspect based patients this Omidubicel. field. risks et of on we're we real Phase contemporaneously the that believe in That on data treated do those submission and study diseases, with of to an the to clinical But characteristic using are cetera. that disease said understanding, explore are not we’re similar world X who the or increase will necessary be our the which focusing

MarkBreidenbach

progress Editas collaboration wondering terms Okay. there has That's cell developing if Editas? your generation if And presentations might recent collaboration Thank next any with preclinical related helpful. And with see of just therapies? to you. NK any been we in finally

JulianAdams

and that I believe active. in did their and is announce has Editas collaboration a previous done longer we calls no interests reprioritized that restructuring

Tracey Lodie

a of now add correct, to is continuing goal program, R&D a hope engineered stage at work but work, targets conference that present XXXX. are a at that collaborator of I'll this work but in with antibodies, that, ADCC enhance But We're providing details which is still other for time, we uniquely an will research we to with the latter we at half just on pre-clinical think which this the combinability GDA-XXX. the improving we will not with with

Operator

from question Markets. RBC have Capital Gregory Renza We a from

line Your is open.

GregoryRenza

morning, the Julian endpoints. to secondary wanted Thanks Omidubicel and question. progress. congratulations mention the the on for I program collection taking start of Good respect continued with just Hey. Julian, Also team. my the to of

you Just in and the characterize a perhaps collection should that to trials question. that of think help pandemic several just you. we Thank experiencing headwinds some can the experience of curious if next data have light of month been how over the weeks some about? That’s the

JulianAdams

it It’s and collecting Ronit Yes. endpoints dealing an all excellent I'll challenges team, who’s the secondary yes. question. to her over turn with of the of with

RonitSimantov

to Absolutely, and to as definitely the sites, yes. time monitoring data. this study challenging research staff Clinical being both thirdly of coming trials available from like as during patients of perspective nurses well are sites,

So all challenges. those are offered

with and of to to facing sites, we with the and can like data. data. the able of that with obtain ability communicate that as challenges ways report We we data secondary not with and our remote these and planned, will are these we variety report will a aware the them endpoints But challenges monitor dealing impact implementation believe things we the and monitoring of be analyze that have

GregoryRenza

helpful. the for That's be the this data fourth starting as And Great. quarter well? BLA would then gating in

RonitSimantov

FDA Phase trial with had we III has so program on meetings met be submission primary trial based bring of endpoint is has we've submission, far. believe forward. will the where regular BLA Phase the in we the order submission clinical the the And that and BLA the can the BLA to how understand III been So basis

fill we've bring those get the and fuller we dataset, package. So submission that Any is as forward. -- we've terms begun to want and about already the in begun we reports put and already talk all those discussions, of in of will And piece we process to those other together

JulianAdams

remind secondary endpoints I study dataset of remain collection would so - endpoints, required a or to not and do secondary the unblind we for influence BLA statistical And with Greg we're we're we blinded submission. for all perform to for blinded and the so safety, others, the as the clinical went blinded activity. just analysis and the report and

Operator

Jason next JMP your Butler comes Securities. have We from question from

is line Your now open.

JasonButler

Hi. taking Thanks question. the for

mentioned you're the me, that over the about continuing to talk payers data that that months, the Just drug comes the to market? you do community. access of in couple III transplant last done receive ensure Julian, one the Omidubicel with Thanks. the you’d work data when for interim? feedback from Phase positive you've the Can you And to on

JulianAdams

Yes.

We have ongoing discussions don't to have the of on coverage. received we've to with and lives, also a payers very dozen we talked largest so And about anticipate million feedback favorable about I the XX reluctance cover basically -- our I to cover for Kite to comment the And just joining Michele and then if for of experiences. playbook product worked can very similar what CAR-T the approval Korfin the team launch any Yescarta.

the we launch joins had her because time the of well. I team have she at for with landscape think where extremely next time insurers to of to secure fortunate plenty time knows And join she major and the very very, we're the So year. contracts the

Operator

a Needham question & from have And Messer we Co. Chad from

Your open. line is

ChadMesser

Good taking questions. morning thanks Great. for my Thanks. and

the different readout just ones to? of wondering I most upcoming of contextualize secondary of should the if that take maybe we ahead prioritize, minute for the be endpoints you which importance the could sort attention paying of and was Just maybe endpoints. of a sort the

JulianAdams

to over again. you Ronit, Yes.

RonitSimantov

Yes. Sure.

that is the analyzed post-transplant. after about note endpoints going six to all are thing first endpoints months to secondary the be are So patients reach that

that of of in involved. the the that isolation the secondary as the main engraftment saying important patients there the we because longer are number complications very to obviously experience quite infection And of well their are platelet patients impact closely for have in that directly clinically patient hospital. to that the neutrophil has will earlier as The also spend time overall all the longer endpoints follow-up with engraftment. and they the post-transplant. are patients that believe hospitalization outcome. outcomes duration patients all So clinical are follow-up have the The and they're and significant Those tied the duration of

endpoints be that patients hit will So once are those really days. XXX those endpoints secondary analyzed

have for Additionally, which underlying survival as also disease set mortality, study disease, evaluation called the comparing will characteristics but we two announce other treatment-related ensure as a with data endpoints factors important should the well overall have is and associated we in are and have to also study. including demographic, but and of outcome which with mortality of other arm, safety and will a the you full are dataset the including non-relapsed we safety full survival, disease-free other full

JulianAdams

very Yes. endpoints very Chad, mentioned it’ll be also have that favorably on treat control, a historical patient a that intent to analysis. we randomized concurrent more obviously based I secondary remind an the in readout larger with you a much but group Ronit so II correlated our data and just robust well-controlled controls, Phase now

So very same value able I the P feel as that. the open-label to reproduce study. that to We think were we'll able the be confident reproduce primary I with II Phase endpoint

go the will of healthcare forward a patients to are system only So be economic of time I to lot the meaningful, with lot benefit these but clinically think attended the that by also to not and a hospitalized. we shortening confidence provide secondary endpoints have

Operator

back to at time. questions conference further to There are I Julian. no would turn this like the you

Julian Adams

that everyone joining for in sharing opportunities data you Thank upcoming the programs to look And really lie call. on the excited We're months. us both about today's ahead. you. Thank from Operator? forward

Operator

call. today's concludes That you. Thank

You disconnect. may now

Jaren Madden	Vice President, Investor Relations and Corporate Communications
Julian Adams	Chief Executive Officer
Ronit Simantov	Chief Medical Officer
Shai Lankry	Chief Financial Officer
Tracey Lodie	Chief Scientific Officer
Ted Tenthoff	Piper Jaffray
Jonathan Mueller	Evercore
Mark Breidenbach	Oppenheimer
Gregory Renza	RBC Capital Markets
Jason Butler	JMP Securities
Chad Messer	Needham & Company

Gamida Cell (GMDAQ) 11 Aug 202020 Q2 Earnings call transcript